NCT02603887 2026-01-29
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
M.D. Anderson Cancer Center
Brigham and Women's Hospital
Emory University
Memorial Sloan Kettering Cancer Center